OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
André Scheen
Diabetes & Metabolism (2020) Vol. 46, Iss. 3, pp. 186-196
Closed Access | Times Cited: 39
André Scheen
Diabetes & Metabolism (2020) Vol. 46, Iss. 3, pp. 186-196
Closed Access | Times Cited: 39
Showing 1-25 of 39 citing articles:
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 230
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 230
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Clifford J. Bailey, Caroline Day, Srikanth Bellary
Current Diabetes Reports (2022) Vol. 22, Iss. 1, pp. 39-52
Open Access | Times Cited: 140
Clifford J. Bailey, Caroline Day, Srikanth Bellary
Current Diabetes Reports (2022) Vol. 22, Iss. 1, pp. 39-52
Open Access | Times Cited: 140
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology
Chinmay Dwibedi, Ola Ekström, J. Leonard Brandt, et al.
Nature Metabolism (2024) Vol. 6, Iss. 1, pp. 50-60
Open Access | Times Cited: 12
Chinmay Dwibedi, Ola Ekström, J. Leonard Brandt, et al.
Nature Metabolism (2024) Vol. 6, Iss. 1, pp. 50-60
Open Access | Times Cited: 12
Pharmacological Management of Glucose Dysregulation in Patients Treated with Second-Generation Antipsychotics
Simona Cernea, Lorena Dima, Christoph U. Correll, et al.
Drugs (2020) Vol. 80, Iss. 17, pp. 1763-1781
Closed Access | Times Cited: 55
Simona Cernea, Lorena Dima, Christoph U. Correll, et al.
Drugs (2020) Vol. 80, Iss. 17, pp. 1763-1781
Closed Access | Times Cited: 55
Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment
Valeria Pellegrini, Rosalba La Grotta, Francesca Carreras, et al.
Cells (2024) Vol. 13, Iss. 19, pp. 1662-1662
Open Access | Times Cited: 5
Valeria Pellegrini, Rosalba La Grotta, Francesca Carreras, et al.
Cells (2024) Vol. 13, Iss. 19, pp. 1662-1662
Open Access | Times Cited: 5
<p>SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients</p>
André Scheen
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 2765-2779
Open Access | Times Cited: 29
André Scheen
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 2765-2779
Open Access | Times Cited: 29
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
The mineralocorticoid receptor in chronic kidney disease
Jonatan Barrera‐Chimal, Frédéric Jaisser, Hans‐Joachim Anders
British Journal of Pharmacology (2021) Vol. 179, Iss. 13, pp. 3152-3164
Open Access | Times Cited: 26
Jonatan Barrera‐Chimal, Frédéric Jaisser, Hans‐Joachim Anders
British Journal of Pharmacology (2021) Vol. 179, Iss. 13, pp. 3152-3164
Open Access | Times Cited: 26
Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes
Nazif Yalçın, Selman Aktaş, Seyit Uyar, et al.
Life (2025) Vol. 15, Iss. 5, pp. 722-722
Open Access
Nazif Yalçın, Selman Aktaş, Seyit Uyar, et al.
Life (2025) Vol. 15, Iss. 5, pp. 722-722
Open Access
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
André Scheen
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 4, pp. 271-282
Closed Access | Times Cited: 9
André Scheen
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 4, pp. 271-282
Closed Access | Times Cited: 9
NEW DIRECTIONS IN PHARMACOLOGICAL TREATMENT WITH SGLT-2 INHIBITOR MOLECULES IN THE LIGHT OF CURRENT GUIDELINES FOR DIABETES MELLITUS, HEART FAILURE AND KIDNEY DISEASE
Mariana Cornelia Tilinca
FARMACIA (2023) Vol. 71, Iss. 4, pp. 686-696
Open Access | Times Cited: 8
Mariana Cornelia Tilinca
FARMACIA (2023) Vol. 71, Iss. 4, pp. 686-696
Open Access | Times Cited: 8
Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Jianping Weng, Longyi Zeng, Yuwei Zhang, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 8, pp. 1754-1764
Closed Access | Times Cited: 16
Jianping Weng, Longyi Zeng, Yuwei Zhang, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 8, pp. 1754-1764
Closed Access | Times Cited: 16
Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
André Scheen
La Presse Médicale (2022) Vol. 52, Iss. 1, pp. 104158-104158
Closed Access | Times Cited: 12
André Scheen
La Presse Médicale (2022) Vol. 52, Iss. 1, pp. 104158-104158
Closed Access | Times Cited: 12
Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia
Benjamin J. Cohen, Yael Harris, Rifka Schulman‐Rosenbaum
Endocrine Practice (2023) Vol. 30, Iss. 4, pp. 402-408
Closed Access | Times Cited: 6
Benjamin J. Cohen, Yael Harris, Rifka Schulman‐Rosenbaum
Endocrine Practice (2023) Vol. 30, Iss. 4, pp. 402-408
Closed Access | Times Cited: 6
Estimation of marginal structural models under irregular visits and unmeasured confounder: calibrated inverse probability weights
Sumeet Kalia, Olli Saarela, Michael Escobar, et al.
BMC Medical Research Methodology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Sumeet Kalia, Olli Saarela, Michael Escobar, et al.
BMC Medical Research Methodology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Cardiovascular effects and mechanisms of sodium‐glucose cotransporter‐2 inhibitors
Fan Yang, Ran Meng, Dalong Zhu
Chronic Diseases and Translational Medicine (2020) Vol. 6, Iss. 4, pp. 239-245
Open Access | Times Cited: 12
Fan Yang, Ran Meng, Dalong Zhu
Chronic Diseases and Translational Medicine (2020) Vol. 6, Iss. 4, pp. 239-245
Open Access | Times Cited: 12
Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: A meta-analysis of observational studies
André Scheen
Diabetes Epidemiology and Management (2022) Vol. 6, pp. 100054-100054
Open Access | Times Cited: 8
André Scheen
Diabetes Epidemiology and Management (2022) Vol. 6, pp. 100054-100054
Open Access | Times Cited: 8
Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment
Jay H. Shubrook, Michael Radin, Sarah Ali, et al.
Advances in Therapy (2022) Vol. 39, Iss. 9, pp. 4114-4130
Open Access | Times Cited: 8
Jay H. Shubrook, Michael Radin, Sarah Ali, et al.
Advances in Therapy (2022) Vol. 39, Iss. 9, pp. 4114-4130
Open Access | Times Cited: 8
Systematic Review of Cardiovascular Outcomes with Sulfonylureas, GLP-1 RA, and DPP-4 Inhibitors in Type 2 Diabetes Mellitus
Thai Hau Koo, Mafauzy Mohamed, Leong Xue Bin
Journal of Diabetology (2024) Vol. 15, Iss. 3, pp. 266-272
Open Access | Times Cited: 1
Thai Hau Koo, Mafauzy Mohamed, Leong Xue Bin
Journal of Diabetology (2024) Vol. 15, Iss. 3, pp. 266-272
Open Access | Times Cited: 1
Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases
Shunsaku Goto, Junya Ishikawa, Masafumi Idei, et al.
American Journal of Case Reports (2021) Vol. 22
Open Access | Times Cited: 10
Shunsaku Goto, Junya Ishikawa, Masafumi Idei, et al.
American Journal of Case Reports (2021) Vol. 22
Open Access | Times Cited: 10
Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Leili Gao, Zhifeng Cheng, Benli Su, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 785-795
Closed Access | Times Cited: 7
Leili Gao, Zhifeng Cheng, Benli Su, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 3, pp. 785-795
Closed Access | Times Cited: 7
The Effect of Empagliflozin on Platelet Function Profiles in Patients with Stable Coronary Artery Disease in Trinidad: The EFFECT Pilot Study
Naveen Seecheran, Arvinash Ramdeen, Niranjan Debideen, et al.
Cardiology and Therapy (2020) Vol. 10, Iss. 1, pp. 189-199
Open Access | Times Cited: 9
Naveen Seecheran, Arvinash Ramdeen, Niranjan Debideen, et al.
Cardiology and Therapy (2020) Vol. 10, Iss. 1, pp. 189-199
Open Access | Times Cited: 9
Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study
S.-C. Liu, C.-C. Lee, Shih‐Ming Chuang, et al.
Diabetes & Metabolism (2020) Vol. 47, Iss. 3, pp. 101184-101184
Open Access | Times Cited: 8
S.-C. Liu, C.-C. Lee, Shih‐Ming Chuang, et al.
Diabetes & Metabolism (2020) Vol. 47, Iss. 3, pp. 101184-101184
Open Access | Times Cited: 8
Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus
Barbara Katharina Geist, Helmut Brath, Lucia Zisser, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 10, pp. 3034-3041
Open Access | Times Cited: 2
Barbara Katharina Geist, Helmut Brath, Lucia Zisser, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 50, Iss. 10, pp. 3034-3041
Open Access | Times Cited: 2
Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus
Shashank Joshi, Vathsala Jayanth, Subramanian Loganathan, et al.
Drugs (2023) Vol. 83, Iss. 13, pp. 1161-1178
Closed Access | Times Cited: 2
Shashank Joshi, Vathsala Jayanth, Subramanian Loganathan, et al.
Drugs (2023) Vol. 83, Iss. 13, pp. 1161-1178
Closed Access | Times Cited: 2
